- Ziggma
- Posts
- 🗞️ Paramount's Hostile Bid for WBD
🗞️ Paramount's Hostile Bid for WBD
Big Moves Decoded: Broadcom, CVNA, and more!
In partnership with
Market Performance
S&P 500: 6,846.51 ⬇️ 0.35%
Nasdaq: 23,545.90 ⬇️ 0.14%
Dow Jones: 47,739.32 ⬇️ 0.45%
A High-Stakes Poker Game
The gloves are off in Hollywood's biggest battle yet. Paramount Skydance (PSKY) is taking its $30-per-share, all-cash offer directly to Warner Bros. Discovery (WBD) shareholders after being shut out by Netflix's (NFLX) winning bid last week.
This hostile takeover attempt – backed by $54 billion in debt from Bank of America, Citi, and Apollo – represents a brazen power play in the rapidly consolidating streaming wars.
What makes this fascinating? CEO David Ellison is betting that cash talks louder than Netflix's stock-and-cash combo.
He's offering shareholders $17.6 billion more in cold, hard cash than Netflix's deal, while throwing shade at their chances of regulatory approval.
"Allowing the No. 1 streaming service to combine with the No. 3 streaming service is anticompetitive," Ellison argued on CNBC.
The financing mix is eyebrow-raising: Saudi Arabia's Public Investment Fund, Abu Dhabi's L'imad Holding, Qatar Investment Authority, and Jared Kushner's Affinity Partners are all backing this play, though they've agreed to forgo governance rights to avoid CFIUS scrutiny.
WBD stock has a Ziggma score of 55 and ranks above most peers in terms of growth and financial health.
The streaming giant has surged more than 150% in the past year and trades at a steep valuation in December 2025.
Our Takeaway
This hostile bid faces an uphill battle. Netflix's $5.8 billion breakup fee and WBD's apparent preference for their deal suggest Paramount is playing a long shot.
While the Trump administration's skepticism toward the Netflix-WBD merger provides an opening, shareholders will ultimately decide if Paramount's cash premium outweighs the strategic value of Netflix's streaming dominance.
Introducing the first AI-native CRM
Connect your email, and you’ll instantly get a CRM with enriched customer insights and a platform that grows with your business.
With AI at the core, Attio lets you:
Prospect and route leads with research agents
Get real-time insights during customer calls
Build powerful automations for your complex workflows
Join industry leaders like Granola, Taskrabbit, Flatfile and more.
Market Overview 📈
Stocks retreated on Monday as investors braced for the Federal Reserve's final meeting of 2025, with all three major indices closing in the red.
The culprit? Rising Treasury yields continue to rattle markets despite near-certain expectations of a quarter-point rate cut this week.
The 10-year Treasury yield extended its December climb, weighing on sentiment even as CME's FedWatch tool shows 89% probability of a rate decrease – up from 67% a month ago.
This disconnect reflects more profound anxieties: inflation concerns heading into 2026 and uncertainty about the Fed's easing path under Chair Jerome Powell, whose term expires in May 2026.
"The market action you've seen the last one or two weeks is essentially baking in the very high likelihood of a 25 basis point cut," said Stephen Kolano of Integrated Partners.
But he warned that if Powell emphasizes data-dependency going forward – especially after November's weak ADP employment figures – "you should start to see more negative pressure on the market in the first half of the year."
Twenty-two S&P 500 stocks hit new 52-week highs, including Electronic Arts (first time since its 1989 IPO) and Warner Bros. Discovery (highest since March 2022).
Stock Moves Deciphered 📈
🧪 Air Products & Chemicals (APD)
Shares plummeted 9.5% after announcing advanced discussions with Yara International for a low-emission ammonia project.
The partnership includes a 25-year hydrogen supply agreement, but investors fear the deal could negatively impact future revenue and market share, triggering a sharp sell-off.
💸 Dollar General (DG)
Stock fell 6.1% as investors took profits following a strong Q3 earnings beat and raised full-year guidance.
The pullback came after a 20% rally in the preceding two days pushed shares near their 52-week high, making the stock vulnerable to profit-taking.
💉 Incyte (INCY)
Shares declined 5.7% despite receiving FDA Breakthrough Therapy designation for its novel blood cancer treatment.
Broader market anxieties surrounding the Federal Reserve's interest rate decision overshadowed the positive development, pressuring the biotech sector and INCY stock.
🛁 Bath & Body Works (BBWI)
The stock gained over 4%, offering a brief reprieve in a brutal year that has seen shares drop by over 50%.
The retailer faces a challenging holiday season with analysts forecasting significant revenue declines, while an ongoing investigation adds to negative sentiment.
Headlines You Can't Miss 👀
🏦 Berkshire Leadership Overhaul: Warren Buffett announces significant management changes, including the departure of investment manager and Geico CEO Todd Combs to JPMorgan Chase, before the year-end CEO transition.
💻 IBM's $11B Acquisition: Tech giant to acquire data streaming platform Confluent in a deal expected to close mid-2026, sending Confluent shares up 29% premarket.
🔬 Thermo Fisher Upgraded: KeyBanc raises rating to overweight with $750 price target (30% upside), citing improved macro conditions and increased R&D spending.
💊 Obesity Drug Breakthrough: Wave Life Sciences soared 140% on positive Phase 1 trial data for an RNA obesity shot that cuts fat while retaining muscle mass.
📈 Semiconductor Milestone: iShares Semiconductor ETF (SOXX) hit a new all-time high, dating back to its 2001 inception, driven by the strength of Broadcom and Teradyne.
🚗 General Motors Upgrade: Morgan Stanley moves to overweight with a $90 target (18% upside), praising the capital allocation realignment and the China business right-sizing.
📡 Fed Meeting Begins: FOMC starts a two-day meeting, with markets pricing in an 89% chance of a quarter-point cut amid inflation and labor market concerns.
👔 V.F. Corporation Slides: Apparel giant dropped 5% as brand weakness and declining earnings pressure shares, compounded by a broader market downturn ahead of the Fed decision.
Trending Stocks 📊
💰Broadcom (AVGO)
Shares jumped nearly 3% and hit a new record high after The Information reported Microsoft is in discussions to design custom chips with Broadcom, potentially shifting business away from Marvell Technology.
The chipmaker continues to benefit from the AI infrastructure buildout and strategic partnerships with hyperscalers.
👕 Five Below (FIVE)
Truist upgraded the off-price retailer to buy with a $216 price target (25% upside), citing "unicorn-like growth" potential.
Despite rallying 65% year-to-date, shares trade below historical averages, while merchandise values and operational efficiencies continue to improve, according to analyst Scot Ciccarelli.
🚗 Carvana (CVNA)
The used car retailer surged 12% following its S&P 500 inclusion announcement effective Dec. 22.
Bank of America raised its price target to $455 (13.8% upside), noting that index fund buying could extend the stock's strong year-to-date performance.
What’s Next?
Key market and macro news 👇
🏦 Federal Reserve concludes two-day FOMC meeting on Wednesday with interest rate decision and Chair Powell press conference.
📊 The NFIB Small Business Optimism Index release provides insight into small business health and economic sentiment.
📰 The Productivity and Costs Report could signal inflationary pressures impacting Fed decisions.
💰Korn Ferry reports Q2 fiscal 2026 earnings before the market opens.
🎤 Oracle quarterly results expected Wednesday amid investor optimism about cloud growth.
Chart of the Day
Meme of the Day
Great investing starts with great information.
Forward The Market Scoop to anyone who wants to stay ahead of the market through a pertinent and entertaining newsletter format.
DISCLAIMER: None of this is financial advice. The newsletter is strictly educational and is not investment advice or a solicitation to buy or sell assets or make financial decisions. Please exercise caution and conduct your own research.